Jagsonpal Pharmaceuticals Ltd Share Price ₹211

Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.

Financials of Jagsonpal Pharmaceuticals Ltd

Quarter-by-quarter operating performance

	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Sales +	55.45	60.15	57.83	47.23	43.49	61.44	74.69	74.03	58.56	75.61	74.47	72.95	64.20
Expenses +	50.01	51.52	49.46	43.83	40.82	51.19	58.40	58.19	49.85	61.41	58.03	56.68	53.04
Operating Profit	5.44	8.63	8.37	3.40	2.67	10.25	16.29	15.84	8.71	14.20	16.44	16.27	11.16
OPM %	9.81%	14.35%	14.47%	7.20%	6.14%	16.68%	21.81%	21.40%	14.87%	18.78%	22.08%	22.30%	17.38%
Other Income +	2.56	2.00	2.27	2.52	2.49	-1.85	1.65	25.51	2.56	2.83	3.03	0.90	3.17
Interest	0.20	0.15	0.22	0.23	0.22	0.22	0.23	0.26	0.26	0.25	0.27	0.26	0.25
Depreciation	0.48	0.39	0.46	0.41	0.40	1.07	2.34	2.41	2.31	2.35	2.39	2.39	2.32
Profit before tax	7.32	10.09	9.96	5.28	4.54	7.11	15.37	38.68	8.70	14.43	16.81	14.52	11.76
Tax %	23.50%	25.87%	25.00%	24.81%	21.59%	25.04%	25.44%	17.27%	24.48%	25.23%	25.22%	24.59%	25.43%
Net Profit +	5.60	7.48	7.47	3.96	3.55	5.33	11.46	31.99	6.58	10.80	12.57	10.95	8.76
EPS in Rs	0.85	1.14	1.14	0.60	0.54	0.81	1.73	4.82	0.99	1.62	1.89	1.64	1.31

Financials of Jagsonpal Pharmaceuticals Ltd

Annual income statement trend

	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Sales +	138	143	144	127	167	159	188	218	237	209	269	287
Expenses +	129	132	138	138	157	150	169	192	203	186	218	229
Operating Profit	9	12	6	-11	9	9	19	26	34	23	51	58
OPM %	6%	8%	4%	-9%	6%	5%	10%	12%	14%	11%	19%	20%
Other Income +	0	1	13	0	1	3	4	3	2	9	28	10
Interest	4	5	3	1	1	1	1	0	0	1	1	1
Depreciation	3	3	2	0	1	1	1	2	1	2	8	9
Profit before tax	2	4	14	-12	9	9	22	27	35	30	70	58
Tax %	30%	20%	18%	-1%	20%	16%	22%	29%	23%	25%	21%	25%
Net Profit +	1	3	12	-12	7	8	17	19	27	22	55	43
EPS in Rs	0.18	0.50	1.81	-1.76	1.10	1.20	2.60	2.88	4.08	3.40	8.34	6.43
Dividend Payout %	22%	8%	2%	-2%	9%	17%	15%	56%	49%	59%	30%	62%

Financials of Jagsonpal Pharmaceuticals Ltd

Capital structure and asset base

	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity Capital	13	13	13	13	13	13	13	13	13	13	13	13
Reserves	82	85	97	85	91	98	109	120	146	174	227	263
Borrowings +	39	38	8	8	4	5	7	0	6	9	9	8
Other Liabilities +	19	22	25	23	28	31	35	31	30	21	29	32
Total Liabilities	154	159	143	130	136	147	164	164	195	217	278	317
Fixed Assets +	52	52	22	21	22	22	26	23	24	9	94	85
CWIP	0	0	0	3	4	4	0	0	0	0	0	0
Investments	0	0	0	0	0	11	15	51	1	0	0	0
Other Assets +	102	108	121	105	110	109	123	91	170	208	184	231
Total Assets	154	159	143	130	136	147	164	164	195	217	278	317

Financials of Jagsonpal Pharmaceuticals Ltd

Operating, investing and financing cash movement

	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Cash from Operating Activity +	4	9	-3	-2	31	11	28	7	47	35	55	47
Cash from Investing Activity +	-0	-2	41	-3	-1	-11	-2	-26	-58	-25	-45	-36
Cash from Financing Activity +	-1	-6	-34	-1	-6	-1	-7	-18	-0	-9	-12	-12
Net Cash Flow	2	1	5	-6	24	-0	19	-36	-11	2	-2	-1
Free Cash Flow	4	6	40	-5	30	12	28	6	48	35	91	47
CFO/OP	53%	83%	-6%	14%	311%	150%	164%	54%	158%	189%	124%	101%

Financials of Jagsonpal Pharmaceuticals Ltd

Working capital efficiency and return ratios

	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Debtor Days	119	106	100	73	45	49	25	26	32	19	18	22
Inventory Days	176	246	295	307	164	191	134	122	82	68	58	51
Days Payable	42	60	56	54	59	76	82	76	66	35	37	40
Cash Conversion Cycle	252	292	339	325	150	164	77	72	48	53	39	33
Working Capital Days	68	72	154	149	67	55	32	59	34	52	9	11
ROCE %	5%	7%	3%	-10%	9%	9%	18%	20%	25%	17%	23%	23%